Articles tagged with Cancer Medication
The UK's first Professor of Teenage and Young Adult Cancer emphasizes the need for improved communication and coordination among pediatricians, oncologists, and other healthcare professionals. Currently, TYA cancer patients often receive sub-standard treatment due to fragmented care.
Researchers have discovered a potential new treatment for breast cancer metastasis to bone, where 70% of patients develop bone metastases. The study found that osteoprotegerin inhibits RANKL, a protein promoting bone breakdown and cancer cell growth.
Researchers developed a nimesulide derivative that selectively inhibits aromatase production in breast cancer cells, reducing the risk of hormone-related side effects. This could lead to more targeted treatments for postmenopausal women with estrogen-dependent breast cancer.
A research team led by Bibiana Bielekova found that daclizumab increases the number of regulatory natural killer cells, which correlates with better treatment outcomes for MS patients. The study suggests that daclizumab may not damage the immune system but rather shifts its reaction from T-cells to natural killer cells.
AACR Public Service Awards recognize Sherry Lansing and Janet Woodcock's dedication to advancing cancer research. Lansing, former Paramount CEO, has raised millions for cancer research through her non-profit advocacy group Stop Cancer, while Woodcock, FDA deputy commissioner, streamlines cancer medicine oversight.
The guidelines aim to help physicians decide when to stop taking medications in older adults. They consider factors such as life expectancy, the time until benefits are realized, goals of care, and treatment targets.
Researchers at Virginia Tech have developed a new anticancer drug that targets DNA using cisplatin-like units. The supramolecular complexes combine light-absorbing PDT agents with the drug, allowing it to bind to cancer DNA and remain inert until activated by a light signal.
Tamoxifen, originally designed as an anti-oestrogen, has proven effective in cancer treatment and is now licensed for preventing breast cancer in high-risk women. Raloxifene, developed to treat osteoporosis, also demonstrates potential in reducing invasive breast cancer risk by 76% in postmenopausal women.
The American Association for Cancer Research (AACR) has conferred its highest honors to several scientists for their groundbreaking contributions to cancer research. Carlo Croce and Wiliam Kaelin received awards for their pioneering work in leukemia and lymphoma research, while Julian Adams was recognized for his discovery of the first...
The study found that patients receiving the combination of paclitaxel and bevacizumab had a significantly improved progression-free survival of 11.4 months, compared to 6.11 months with paclitaxel alone. This trend also suggested improved overall survival in patients treated with the new drug combination.
Researchers found that low-intensity electrical stimulation increased the uptake of doxorubicin in cancer cells, causing them to die even at low concentrations. This novel strategy could bypass multidrug resistance and enhance the efficacy of existing chemotherapeutic treatments.
The study found that the percentage of women receiving adjuvant chemotherapy who received taxanes such as paclitaxel increased more than sevenfold after early 1998, with rates rising in both node-positive and node-negative breast cancer. The authors suggest that publicity at ASCO and media coverage contributed to this shift.
A randomized Phase III clinical trial found decitabine improved treatment outcomes for myelodysplastic syndrome patients, achieving a 17% complete response rate. The median time to progression was also significantly longer in treated patients compared to those receiving supportive care.
Researchers found decitabine improves disease-free periods, quality of life in MDS patients. New drug offers little survival benefit but improves quality of life and has some quality of life benefits compared to supportive care.
Researchers found PDT to be highly effective against drug-resistant bacteria and fungus, including S. mutans and Candida species, with minimal doses of light required to kill nearly all organisms.
Researchers developed a new way to study proteins in live cells, identifying interactions between Src and CrkL, and direct evidence of its role in MAP kinase pathways. This approach may lead to the development of new cancer treatments, such as targeting tyrosine kinases like Gleevec.
Duke University scientists increased chemotherapy drug molecular weight to improve tumor penetration and concentration while reducing healthy tissue toxicity. The optimal molecular weight range was found to be between 40,000 and 70,000.
A cancer researcher is working on a targeted way to deliver drugs to specific cells, making treatment more precise and effective. The approach uses natural biomolecules to target diseased cells while leaving healthy ones alone.
Rice University's bioengineering Ph.D. students will receive comprehensive training in cancer biology, clinical medicine, and translational research through a unique partnership with MD Anderson. The program aims to revolutionize the translation of cancer knowledge into new technologies for detection and treatment.
A new MRI drug, mangafodipir, has been found to improve the effectiveness of chemotherapy by increasing antitumoral activity while protecting normal cells from damage. The study suggests that mangafodipir may enhance the therapeutic index of anticancer agents and supports investigation into its use in cancer patients.
Parallel administration of chemotherapy and darbepoetin alfa every 3 weeks is safe and effective in treating anemia. Gene expression profiling may provide more accurate information for certain high-risk breast cancers than laboratory examination alone.
Researchers have identified small molecules called indoxins that can potentiate the effectiveness of doxorubicin in E6-expressing colon cancer cells. The compounds drive two distinct cell cycle-related mechanisms, overcoming E6-induced drug resistance and increasing sensitivity to chemotherapy.
Cedars-Sinai researchers discovered a biochemical pathway that makes gliomas and other cancer cells more sensitive to TRAIL, a protein inducing apoptosis in cancer cells. By combining TRAIL with pioglitazone, a diabetes drug, they aim to enhance the effectiveness of therapies targeting cancer cells.
Researchers believe that understanding the structure of DNA end caps, called telomeres, can help develop new cancer treatments. They found that the rate of shortening is influenced by the length of the overhang and hope to manipulate it for therapeutic purposes.
A study has found that vaginal oestrogen can increase systemic oestradiol levels in women on aromatase inhibitors (AI) for breast cancer, potentially counteracting AI treatment. Researchers recommend avoiding the combination of AIs and vaginal oestrogens, except in exceptional circumstances.
Researchers have developed a 'nanoshuttle' that uses viral particles to precisely home to disease, where it can perform various functions such as destroying tissue or emitting signals. The system has the potential to deliver stem cells to damaged areas, potentially treating heart disease and cancer.
The Vilcek Foundation honors Dr. Massagué's work on controlling cell behavior and its connection to cancer development. The prize recognizes his contributions to the field of cancer biology and genetics.
Researchers have identified a growth control flaw in some aggressive breast cancers, linked to overactive cyclin D1 and CDK4 kinase. The finding could pave the way for new therapies targeting this deadly subtype of breast cancer.
Researchers found that bexarotene reduced tumor burden by almost 50% and inhibited malignant tumor progression by about 50% in mice. The study suggests bexarotene is a potentially viable lung cancer prevention candidate.
Researchers found that human kidney cancer cells lacking the tumor suppressor gene Von Hippel Lindau were more sensitive to CCI-779 due to high levels of hypoxia-inducible factor (HIF). The study identified a test to predict which patients will benefit from receiving CCI-779, potentially helping 20,000 kidney cancer patients annually.
Researchers at St. Jude Children's Research Hospital have made significant progress in treating Acute Lymphoblastic Leukemia (ALL), with a reported 90% cure rate. The improvements are attributed to the effective use of existing drugs, genetic technologies, and personalized treatments.
A new clinical trials method is proposed to improve patient care by incorporating Bayesian approaches in trial design. The frequentist statistical method used today is considered too rigid and limits innovation, whereas the Bayesian approach allows for continuous updating based on interim results.
A study of primary-care patients found that genetic variations can affect the metabolism of common medications, potentially leading to adverse reactions. The researchers suggest that applying pharmacogenetics in primary-care practices could reduce costs by minimizing unnecessary prescriptions and hospital treatments.
Researchers found that combining trastuzumab, an antibody targeting HER2 protein, with immune-stimulating agents like IL-12 can activate the immune system to attack tumor cells more effectively. This combination may improve treatment outcomes for breast cancer patients.
A large study of over 4000 participants found no association between statin use and reduced risk of colorectal cancer. The researchers noted that if statins strongly reduced the risk, any cholesterol-lowering drug would likely show some reduction in risk due to shared users.
A meta-analysis of randomized controlled trials found that statins did not reduce the incidence of cancer or cancer death. The study evaluated 86,936 participants and 26 trials, with no reductions noted for specific types of cancer.
Two new studies uncover significant associations between certain autoimmune disorders and an increased risk of non-Hodgkin lymphoma. Meanwhile, a separate study suggests that consuming carbonated soft drinks may decrease the risk of esophageal adenocarcinoma, contrary to previous findings.
Researchers designed a new trinuclear platinum compound with enhanced cellular absorption, which targets cancer cells and reduces resistance. The novel compound's non-covalent interactions minimize side effects and improve its effectiveness against common human cancers.
J. Virgil Waggoner is being recognized by the Chemical Heritage Foundation for his outstanding contributions to the petrochemical industry, as well as his commitment to education and community service. He will receive the Petrochemical Heritage Award at the opening of the 31st annual NPRA International Petrochemical Conference.
The study reveals that the EBNA3C protein recruits a complex to degrade the retinoblastoma protein (Rb), leading to uncontrollable cell proliferation. This finding holds promise for developing new treatments for EBV-associated B cell lymphomas and other blood cancers.
A recent study by Mayo Clinic researchers found that only about 4.5% of aggressive kidney tumors express KIT, a receptor kinase tyrosine, and no mutations were detected in most cases. This suggests that imatinib therapy may not be effective for these patients, despite previous studies suggesting its potential benefits.
A study found that informational campaigns alone may not be enough to increase participation in cancer clinical trials among black and Asian American patients. Lack of awareness about trial costs being covered by insurance is a significant barrier to participation, especially among those with lower incomes and education levels.
Researchers studied early heart development using Drosophila genetics, finding that Slit and Robo proteins play a critical role in proper alignment of heart tube cells. This misalignment can lead to observed heart defects, and the study may soon be applied to develop diagnostic tests for congenital heart defects.
Women with the CYP2D6 genetic variant were more likely to experience breast cancer recurrence when treated with tamoxifen. Researchers also found that this group was less likely to suffer from hot flashes, which may predict the gene variation.
Researchers at the Burnham Institute, along with partners from six institutions, are working on a NCI-funded project to develop an accurate early-stage diagnosis method for prostate cancer. The goal is to identify specific gene products indicative of the disease's clinical behavior.
Researchers found encouraging preliminary findings in four patients with CLL who improved after taking EGCG, an extract of green tea. However, more studies are needed to determine the optimal dose and side effects before recommending widespread use.
Researchers found marked improvement in chronic myeloid leukemia and acute lymphocytic leukemia patients treated with AMN107. The drug, taken in pill form, outperforms Gleevec by up to 50 times in shutting down cancer-causing tyrosine kinase.
A new study conducted at Ohio State University found that combining the immune substances IL-12 and interferon is safe for patients with advanced cancer. The treatment combination was shown to stop disease progression in five patients for at least six months, with no serious side effects reported.
A study by Northwestern University found that a major sales promotion effort by AstraZeneca and TAP Pharmaceuticals led to significant income increases for urologists. The switch to Average Sales Price-based Medicare reimbursement is expected to decrease oncologists' revenue by 8%.
Researchers found that chemotherapy with doxorubicin and cisplatin extended disease-free survival by 50% and overall survival by 13% compared to radiation therapy. Serious side effects were more common in the chemotherapy group, but a new regimen may be less toxic.
A study found that Ack1 is a key driver of tumor growth in prostate cancer, and its inhibition can slow tumor formation. The researchers also discovered an experimental drug called geldanamycin that can inhibit Ack1 activity by interfering with its molecular interactions.
Researchers at Johns Hopkins Medicine have identified a new therapeutic target for drugs to treat multiple sclerosis (MS) and other autoimmune diseases. By targeting dendritic cells, the researchers hope to stop faulty immune responses at an upstream level.
New research suggests that Herceptin may be cost-effective for certain sub-groups of patients with early breast cancer, but its use as adjuvant therapy could impose a significant financial burden on healthcare systems. The study estimates that the cost of providing Herceptin treatment in Belgium would be around €25.5 million per year.
A University of Minnesota study reveals that nearly 20% of childhood cancer survivors experience physical limitations and trouble performing daily activities. Survivors of brain and bone cancers are most affected, with many reporting difficulties attending work or school.
UC Davis researchers have discovered a genetic switch, Ku86, involved in cells' response to radiation therapy. The switch, when turned off, enhances the effectiveness of radiation therapy with less toxicity than current radiosensitizing drugs.
Researchers investigate compounds like thalidomide, arsenic, and insecticide-derived drugs for their potential to treat solid tumors and various types of cancers. These novel approaches aim to overcome resistance to existing treatments and reduce adverse effects associated with hormonal ablation therapy.
Researchers have discovered a protein, RAR1, critical for response to retinoid treatment, which is resistant to this class of drugs. By triggering RAR1 protein expression in cancer cells, sensitivity can be restored, offering new hope for lung cancer patients.
A new combination treatment for glioblastoma has been found to improve survival rates without negatively affecting patients' quality of life. The study, which involved 573 patients, found no significant differences in six out of seven health-related quality of life measures after three months.
A follow-up study to the NSABP Breast Cancer Prevention Trial confirms tamoxifen's effectiveness in reducing invasive and noninvasive breast cancer risk. The study found a 43% reduction in invasive breast cancer risk and a 37% reduction in noninvasive breast cancer risk.
Researchers at VCU Massey Cancer Center have successfully combined two novel drugs to treat breast cancer, achieving profound tumor cell death in a short period. The combination of UCN-01 and a MEK 1/2 inhibitor shows great potential for treating various types of cancer.